Eyeforpharma Real World Evidence Conference Round up 2018
Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)
This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions.
Eyeforpharma – Real World Evidence 2018
16-17 May in Tokyo, Japan
Research Partnership is delighted to be attending the Eyeforpharma Real World Evidence (RWE) conference in Tokyo, Japan 16-17 May. RWE is currently a very hot topic for the Japanese pharma industry, with an increased push to place RWE as a strategic imperative for pharma.
Innovation, sustainability and prosperity: Japan’s healthcare vision for the future
By Callum McCulloch and Marc Yates
In 2015, the Japanese government appointed an advisory panel of young experts to lay out its vision of healthcare in the country for 2035. This vision is a healthcare system that delivers unrivalled health outcomes, provides secure and responsive care for all in society, is sustainable, and contributes to prosperity in the nation and around the world.
Yet, how achievable is this ideal, and how does the government plan to realize its vision? What is clear is that it will require a paradigm shift – a move from quantity to quality of care and from inputs to value, on care rather than cure, on autonomy over regulation, on national integration rather than fragmentation.
North Asia infographic
North Asia's largest markets; China, Hong Kong, Japan, South Korea and Taiwan, are home to more than 1.6 billion people and is a key global growth region. With pharmaceutical sales of more than $215bn, it is an attractive region for pharma, however one in which each market differs in terms of opportunities and challenges.